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Abstract
Background: The ongoing COVID-19 outbreak has caused devastating mortality and posed a significant threat to
public health worldwide. Despite the severity of this illness and 2.3 million worldwide deaths, the disease
mechanism is mostly unknown. Previous studies that characterized differential gene expression due to SARS-CoV-2
infection lacked robust validation. Although vaccines are now available, effective treatment options are still out of
reach.
Results: To characterize the transcriptional activity of SARS-CoV-2 infection, a gene signature consisting of 25 genes
was generated using a publicly available RNA-Sequencing (RNA-Seq) dataset of cultured cells infected with SARS-
CoV-2. The signature estimated infection level accurately in bronchoalveolar lavage fluid (BALF) cells and peripheral
blood mononuclear cells (PBMCs) from healthy and infected patients (mean 0.001 vs. 0.958; P < 0.0001). These
signature genes were investigated in their ability to distinguish the severity of SARS-CoV-2 infection in a single-cell
RNA-Sequencing dataset. TNFAIP3, PPP1R15A, NFKBIA, and IFIT2 had shown bimodal gene expression in various
immune cells from severely infected patients compared to healthy or moderate infection cases. Finally, this
signature was assessed using the publicly available ConnectivityMap database to identify potential disease
mechanisms and drug repurposing candidates. Pharmacological classes of tricyclic antidepressants, SRC-inhibitors,
HDAC inhibitors, MEK inhibitors, and drugs such as atorvastatin, ibuprofen, and ketoconazole showed strong
negative associations (connectivity score < − 90), highlighting the need for further evaluation of these candidates
for their efficacy in treating SARS-CoV-2 infection.
Conclusions: Thus, using the 25-gene SARS-CoV-2 infection signature, the SARS-CoV-2 infection status was
captured in BALF cells, PBMCs and postmortem lung biopsies. In addition, candidate SARS-CoV-2 therapies with
known safety profiles were identified. The signature genes could potentially also be used to characterize the COVID-
19 disease severity in patients’ expression profiles of BALF cells.
Keywords: COVID-19, SARS-CoV-2 gene expression signature, Bronchoalveolar lavage fluid cells, Peripheral blood
mononuclear cells, COVID-19 treatments
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Background
The 2019 coronavirus pandemic (COVID-19), caused by
the novel Severe Acute Respiratory Syndrome Corona-
virus 2 (SARS-CoV-2), has already contributed to over
107 million confirmed cases and 2.3 million deaths
worldwide [1]. The Centers for Disease Control and Pre-
vention (CDC) has developed test kits to diagnose the
SARS-CoV-2 virus RNA from nasopharyngeal (NP) or
oropharyngeal (OP) swabs using real-time reverse tran-
scription polymerase chain reacton (RT-PCR) [2, 3].
However, the detection of SARS-CoV-2 RNA was shown
to be much higher with NP swabs than OP swabs, 63%
compared to 32%, respectively [4]. Therefore, sputum or
BALF may be better suited for the detection of the
SARS-CoV-2 virus due to the high viral load observed in
BALF [5]. Despite previous advancements in our know-
ledge of SARS-CoV-2, significant gaps still exist within
our understanding of COVID-19 and clinical care, such
as the uncertainty of mortality risk in critically ill pa-
tients. However, publicly available studies and datasets
can be further leveraged to learn more about COVID-19
pathophysiology and treatment [6].
Beyond diagnostic procedures, understanding the
mechanisms of action to begin the formulation of poten-
tial drug therapies is crucial. Previous studies have
shown that SARS-CoV-2 infection begins with SARS-
CoV-2 viral entry through a host receptor, angiotensin-
converting enzyme 2 (ACE2) [7]. The cellular serine pro-
tease TMPRSS2 is also a susceptibility factor since it
primes the spike protein of SARS-CoV-2 [8, 9]. ACE2
and TMPRSS2 are primarily expressed in bronchial tran-
sient secretory cells, nasal and mouth tissues [9, 10].
Therefore, drug therapies inhibiting SARS-CoV-2 inter-
action with ACE2 or TMPRSS2 may be promising for
COVID-19 treatments. On the other hand, up-
regulation of ADAM17 has been shown to leads to the
ACE2 ectodomain proteolytic cleavage in which regula-
tion of the ADAM17/ACE2 axis may be a potential tar-
get by treatments such as paricalcitol, a synthetic
vitamin D analog [11, 12]. Additional drug target therap-
ies have also been proposed, such as recombinant sol-
uble ACE2, indirect ACE2 modulators (angiotensin
receptor blockers, calmodulin antagonists, selective es-
trogen receptor modifiers), TMPRSS2 inhibitors (camo-
stat, nafamostat, antiandrogens, inhaled corticosteroids),
and ADAM-17 enhancers (5-fluorouracil) [12]. Since
drug development and approval of a new treatment is a
critically lengthy process to ensure safety and effective-
ness, repurposing currently available drugs with known
safety profiles is a lucrative strategy. Initially, a few
repurposed drugs, including chloroquine, hydroxychlor-
oquine, lopinavir/ritonavir, ribavirin, oseltamivir, were
thought to be promising. However, there is a lack of
strong evidence supporting the effectiveness of these
therapies against COVID-19 [13–15]. Although intra-
venous remdesivir has now been approved by the US
Food and Drug Administration (FDA) due to its proven
efficacy in multiple clinical trials in reducing critically ill
COVID-19 patients recovery time by 5 days, effective
treatment options are limited [15, 16]. As adjunctive
therapy, supporting evidence of the role of corticosteroid
in COVID-19 treatment has also been inconsistent. The
Randomized Evaluation of COVid-19 thERapY (RECOV-
ERY) trial has shown a significant reduction of death by
35% in ventilated patients and 20% in patients on sup-
plemental oxygen therapy with dexamethasone in severe
cases [17]. Further advancements are currently under
investigation in clinical trials underway with many
antivirals, anti-cytokines, immunomodulatory, and im-
munoglobulin agents as COVID-19 treatment to im-
prove current therapies [13].
Gene expression signatures, representing transcrip-
tional activities of a disease or biological phenomenon,
can be utilized to potentially identify novel drug targets
for COVID-19. This method has been applied to
characterize many conditions, including cancer effect-
ively, and used to identify potential treatments for many
years [18, 19]. Essentially, gene expression signatures
consist of the most discriminatory differentially
expressed genes for a disease or biological phenomenon.
Application of gene expression signatures has been used
for viral infection or severity of infection assessment. Re-
searchers have developed virus infection signature of
dengue and other viruses to assess severity of infection,
secondary infection, reservoirs in hosts, or origin of “or-
phan viruses” [20, 21]. Differentially expressed genes
(DEGs) studies have also been conducted for SARS-
CoV-2 infection [22]. However, these DEGs studies were
not robustly validated in independent datasets or differ-
ent cell types with SARS-CoV-2 infections.
In this study, we sought to characterize the transcrip-
tional response to SARS-CoV-2 infection by generating
a gene expression signature, a set of genes representing
infection in the host that can be used as a surrogate
measure of the infection-related transcriptional activity,
using a publicly available dataset derived from infecting
cultured cells with SARS-CoV-2 [19, 23–26]. The gene
signature was then validated in independent datasets
(CRA002390, SRR10571724, SRR10571730, and
SRR10571732) from COVID-19 patients, specifically in
BALF cell and peripheral blood mononuclear cell
(PBMC) samples [22]. The signature genes were also in-
vestigated in a single-cell RNA-Sequencing (scRNA-Seq)
dataset (GSE145926) to evaluate the role of genes’ ex-
pression in COVID-19 disease severity [27]. Finally, the
signature genes were assessed for similar perturbations
and potential drug targets by using ConnectivityMap
(CMAP) database.
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Results
Signature generation and validation
To develop a gene expression signature representative of
COVID-19, a computational analysis tool known as
Adaptive Signature Selection and InteGratioN (ASSIGN)
was used on cell lines infected with SARS-CoV-2
(GSE147507). An optimal SARS-CoV-2 infection signa-
ture of 25 genes was generated consisting of 12 upregu-
lated and 13 downregulated genes (Table 1, Fig. 1a).
Genes that showed the highest discrimination between
the control and SARS-CoV-2 infected training samples
were selected. Leave-one-out-cross-validation (LOOCV)
plot demonstrated an internal validity of the signature
displaying infection activity of the samples. The 12 sam-
ples infected with SARS-CoV-2 showed high infection
activity, while the control samples showed no infection
activity (Fig. S1). Ingenuity Pathway Analysis (IPA) re-
vealed that ‘Interferon Signaling’ and ‘Role of Pattern
Recognition Receptors in Recognition of Bacteria and
Viruses’ pathways were significantly enriched for genes
differentially expressed in SARS-CoV-2 infected cell
lines compared to mock-treated cells (P-value = 2.37 ×
10− 13 and 7.37 × 10− 11, respectively; Fig. S2).
Next, the gene signature was further tested in two
series from the same GSE147507 dataset for additional
internal validation (Fig. 1b). Series 2 contained A549
cells with mock or SARS-CoV-2 (Multiplicity of Infec-
tion MOI, 0.2) infection, while series 15 contained lung
samples from postmortem otherwise healthy or COVID-
19 patients Series 2 contained A549 cells that were not
well-infected with SARS-CoV-2 virus [26]. The signature
detected higher infection activity in the infected cell
lines than in control samples as well as predicted high
infection activity in lung biopsy samples from pa-
tients with COVID-19 and no infection in healthy sam-
ples. In low-level SARS-CoV-2 infected A549 cells, the
signature detected higher infection in the infected sam-
ples but at a lower level than the lung biopsy with
COVID-19 patient samples. Thus, the 24-hour post-
infection SARS-CoV-2 signature accurately predicted in-
fection status during internal validation in the postmor-
tem lung samples from COVID-19 patients and cell
lines with very low SARS-CoV-2 infection.
Finally, the 25-gene signature was validated in an inde-
pendent external validation dataset with seven BALF
cells and six PBMC samples from COVID-19 patients
(CRA002390, SRR10571724, SRR10571730, and
SRR10571732; Fig. 1b). All infected patients’ samples
were predicted to have higher infection activity com-
pared to healthy control samples (mean predicted activ-
ity: 0.958 vs. 0.001; P < 0.0001). Thus, the signature was
internally tested and then further validated in an exter-
nal independent dataset from multiple COVID-19 pa-
tient samples.
Expression patterns of a gene signature in scRNA-Seq
Following signature validation, the signature genes were
evaluated in scRNA-seq data (GSE145926) to assess
their roles in SARS-CoV-2 infection severity. The signa-
ture genes were investigated in BALF cells from six pa-
tients with severe COVID-19 disease, three patients with
moderate COVID-19 disease, and three healthy controls.
Using cell markers, Uniform Manifold Approximation
and Projection (UMAP) clustering analysis, eight types
of cells were identified, including macrophages, basal
cells, dendritic cells, naïve CD4+ T cells, neutrophils,
natural killer (NK) cells, plasma cells, and T cells (Table
S1, Fig. S3). Higher counts of neutrophils, basal and den-
dritic cells were found in BALF cells from severe
Table 1 25-gene SARS-CoV-2 infection signature. The 25-gene
SARS-CoV-2 infection signature listing the genes with positive
and negative weights indicating upregulated and
downregulated expression, respectively. Twelve genes are
upregulated and 13 genes are downregulated in the SARS-CoV-
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COVID-19 patients compared to healthy controls
(Fig. 2a, Fig. S4-S10a). In basal, dendritic, and T cells,
CXCL2, TNFAIP3, MAFF, PPP1R15A, NFKBIA showed
higher expression levels in severely infected patients
than mildly infected patients and healthy controls (Fig.
2b, and Fig. S4-S10b).
Fig. 1 Development and validation of the 25-gene SARS-CoV-2 signature. a 25 gene SARS-CoV-2 signature using cell lines A549 overexpressed
with ACE2 and Calu-3 infected with SARS-CoV-2 (Multiplicity of infection [MOI] 2) compared to mock-treated. b Internal and external validation of
SARS-CoV-2 infection activity by using the signature in series 2, 15, bronchoalveolar lavage fluid (BALF) cells (n = 7) and peripheral blood
mononuclear cells (PBMC) (n = 6) samples. Series 2 consisted of A549 cells infected with mock or SARS-CoV-2 (MOI 0.2), whereas series 15
consisted of postmortem COVID-19 patients and healthy lung biopsy samples. BALF cells and PBMC were collected from healthy and SARS-CoV-2
infected patients
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To explore the feature distributions of the signa-
ture genes in infected patients and healthy controls,
ridge plots were studied for the 14 genes shared be-
tween the signature and the sc-RNA dataset. (Fig. 2c
and Fig. S4-S10c). In general, the gene expression
distributions were similar in mildly infected patients
and healthy controls compared to severely infected
patients. Some signature genes showed differential
expression in various immune cells and may indicate
the severity of the infection. Specifically, among the
upregulated signature genes, TNFAIP3, PPP1R15A,
NFKBIA, IFIT2 had bimodal gene expression distribu-
tions in the immune cells from severely infected pa-
tients compared to healthy or mildly infected patients,
while the chemokine genes or chemokine inducible
genes, IL1A, CXCL2, CXCL3, CCL20, and PTX3 showed
minimal variance. Compared to other cells, IFIT2 had
lower expression levels in a majority of the plasma cells
from patients with severe disease compared to patients
with moderate disease and healthy controls. Among the
downregulated signature genes, UPC2 showed slightly
decreased expression in dendritic cells, macrophages,
and NK cells from patients with severe disease com-
pared to healthy or infected individuals with moderate
COVID-19 disease. DHCR24 and TPPP3 genes showed
limited to no variance in the infection severity.
Analysis of signature genes for perturbagen evaluation
To characterize the patterns of SARS-CoV-2 transcrip-
tional activity in existing datasets, a gene expression
query was performed using these 25 genes in the CMAP
database. There were 493 strong connections with the 25-
gene signature in the CMAP database characterized by con-
nectivity scores (CS), of which 45 were treatments with vari-
ous pharmacologic compounds. Genetically, the SARS-CoV-
2 infection signature was most alike in conditions where
NFkB was activated via overexpression of various tumor ne-
crosis factor receptor family genes (CS 99.9), knockdowns of
heat shock proteins, and vesicular transport (CSs 97.7 and
96, respectively). Knockdowns of SYPL1, NDUFB6, RYBP,
multiple G-protein coupled receptors (GPCRs), including
purinergic receptor P2RY2, multiple CD molecules, PRPF4,
IL8, RPIA, TAF15, PCGF3, LSS, CXCL2, and CCDN2, were
strongly negatively (CS <− 95) connected with the signature.
Pharmacologically, MEK inhibitors, SRC inhibitors, and tri-
cyclic antidepressants (TCAs) were found to have the most
opposing signature to the SARS-CoV-2 infection signature
(CSs − 98.7, − 95.1 and− 92, respectively). These drugs may
oppose the effects of SARS-CoV-2 viral infection. Many
HDAC inhibitors, growth-factor targeting drugs, dopamine
receptor inhibitors, ibuprofen, ketoconazole, chromamycin-
a3, and atorvastatin showed strong negative connections
(Fig. S11, Fig. 3), suggesting these drugs may have a
Fig. 2 Expression of signature genes in neutrophils from respective patient groups. a Uniform Manifold Approximation and Projection (UMAP)
plots of the neutrophils. Each dot corresponds to one single cell. b Heatmap of fourteen signature genes in three groups. Each vertical bar
represents a single cell. Column (cell identity) width is proportional to the number of cells present in that cluster. c Distributions of signature
gene expression shown in ridge plots. Red, blue and green colors represent gene expression values in severe, mild patients and healthy
controls, respectively
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modulating effect in SARS-CoV-2 infection. Additionally,
CSs were also composed of other potential drugs available
in the CMAP database that are currently or were previ-
ously considered for COVID-19 treatments, including
chloroquine, ribavirin, angiotensin-converting en-
zyme (ACE) inhibitors / angiotensin receptor blockers
(ARB), lopinavir, dexamethasone, and other glucocorti-
coids. None of these had a strong connection with our
query signature (Table S2). The antiviral with the stron-
gest negative connection was ritonavir (CS − 82.9).
Discussion
Infection of the SARS-CoV-2 virus can wreak havoc on
the body and cause severe pulmonary disease. Currently,
we lack an adept understanding of disease mechanisms
and effective drug therapy for this fatal disease [22]. As
new variants continue to emerge, the scientific commu-
nity and healthcare officials are racing to find effective
COVID-19 treatments and vaccines. A gene expression
signature capable of effectively characterizing the host
transcriptional activity resulting from the infection can
Fig. 3 Pharmacologic signature connections identified in the ConnectivityMap (CMAP) database. a Distribution of strong connectivity scores (CS) for the top
three pharmacologic classes with 4 or more compounds. b Bar plot of individual pharmacologic compounds. Positive CSs indicate the degree of similarity
and negative CSs indicate the degree of dissimilarity. -90 > = CS or CS > = 90 was considered strong dissimilar and similar connections, respectively
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be translated to a biomarker for treatment selection.
Multiple publicly available datasets were leveraged and a
flexible Bayesian factor analysis approach was used to
develop and validate a SARS-CoV-2 infection signature
consisting of 12 upregulated and 13 downregulated
genes. These genes were profiled in single cells obtained
from BALF cells of healthy and infected patients to as-
sess transcriptional variance in disease severity. Further-
more, the signature was applied to CMAP, a publicly
available gene expression signature database, to identify
drugs that oppose this signature and could serve as po-
tential drug candidates for treating SARS-CoV-2 infec-
tion. Finally, the SARS-CoV-2 infection mechanism
influencing potential drug choices for repurposing was
proposed (Fig. 4).
From our current understanding, the mechanism of
action for SARS-CoV-2 viral entry is that the virus en-
ters the cells through ACE2 receptors facilitated by
TMPRSS2 spike proteins and activates the renin-
angiotensin (RAS) system. The RAS system controls
many critical aspects of the circulatory system, includ-
ing bradykinin (BK) regulation of blood pressure.
Current evidence suggests that a subgroup of patients
with severe COVID-19 may experience “cytokine
storm” syndrome indicating an extreme host immune
response [15, 28]. Targeting IL-6, IL-1, and JAK/STAT
protein can be used as approaches to suppress the
cytokine storm [29]. Other studies propose an alter-
nate theory in COVID-19, a “bradykinin storm.” The
bradykinin storm theory can explain many of the
symptoms of COVID-19. Angiotensin-converting en-
zyme (ACE) typically degrades BK, but the SARS-
CoV-2 virus downregulates ACE. Thus, more BK re-
mains active. As BK builds up, so does the vascular
permeability. As a result, the lungs fill with fluid, and
immune cells leak into the lungs, causing severe
inflammation.
Bradykinin receptors are GPCRs and are known for
their role as proinflammatory mediators [30]. Proinflam-
matory mediators such as chemokines (CXCL2, CXCL3,
CCL20), BK, tumor necrosis factors, and interleukins
stimulate GPCRs and activate intracellular MAPK, NF-
kB, and MAFF dependent inflammatory pathways [31].
IFIT2 expression has also been shown to induce proin-
flammatory cytokine response both in vitro and in vivo.
Activation of the MAPK/NF-kB signaling pathway, in
turn, upregulate airway kinin receptors leading to air-
way hyperreactivity [32]. Knockdowns of other
GPCRs, including GPR137, GPR65, purinergic recep-
tor P2RY2, were strongly negatively connected with
the signature, indicating potential interaction with in-
flammatory pathways and platelet adhesion [33].
Therefore, the roles of these GPCRs need to be fur-
ther investigated in COVID-19.
Among the other signature genes, upregulation of
NFKBIA has been associated with the survival, activa-
tion, and differentiation regulation of immune cells [34].
ACE2 mediated activation of ACE/AngII/AT1R axis lead-
ing to hyperactivation of NFKBIA, ultimately precipitat-
ing cytokine storm in COVID-19 patients [35]. Under
the normal physiologic condition, ACE/Ang II/AT1R axis
activation is compensated by Ang-(1–7) and downregula-
tion of the NFKBIA expression [35]. However, studies
show that the activation of NF-kB and MAPK pathways
results in the induction of inflammatory genes [36]. Ab-
errant TNFAIP3 expression could also lead to inflamma-
tion and tissue damage [37]. Consistent with these
studies, we found the number of neutrophils was higher
in severe COVID-19 patients, and these patients had a
higher expression of NFKBIA and TNFAIP3 than the pa-
tients with mild or no infection [38].
Particularly, the P2Y2 receptor (P2Y2R), encoded by the
P2RY2 gene, is implicated in a wide range of inflammatory
lung diseases whose pathogenesis overlaps with SARS-
CoV-2 [39]. P2Y2R is activated by extracellular nucleotides
ATP and UTP, which are released from cells upon injury
or stress and play a major role in the initiation and main-
tenance of inflammation and immune modulation [39].
For instance, P2Y2R activation by ATP stimulates neutro-
phil recruitment into lungs, the release of neutrophil
granular content, and directed migration of dendritic cells
and eosinophils [40–43]. Besides, P2Y2R is expressed on
pulmonary endothelial cells and its activation enhances
VCAM-1 expression facilitating leukocyte adhesion [44].
P2Y2R activation on airway epithelium mediates secretion
of mucin and the proinflammatory cytokine IL-33 [28, 45].
In addition to IL-33, P2Y2R mediates the production of
several cytokines that are directly implicated in SARS-
CoV-2 pathogenesis, including IL-6, IL-1β, TNF-α, CXCL-
10, and IFN-γ [46–48]. Interestingly, IFN-γ, paralleled with
P2Y2R, is strongly associated with our proposed signature.
Furthermore, P2Y2R is known to cooperate with
pannexin-1 (PANX-1) channel protein that mediates pas-
sive transport of ATP, which triggers lung inflammation
and regulates the life cycle of multiple viruses through en-
hancing viral binding to host cells, uptake, and replication
[49–53]. Hence, PANX-1 and probenecid (an FDA-
approved PANX-1 inhibitor) have been recently suggested
for further investigation in the efforts to develop a
COVID-19 treatment [54]. Collectively, our signature cor-
relations, consistent with a large body of literature, suggest
a potential role for P2Y2R in the pathogenesis of SARS-
CoV-2.
IFIT inhibits virus replication by binding, regulating
the functions of cellular, viral proteins, and RNAs [55].
IFIT2 possesses antiviral activity against the SARS-CoV-
2 virus by acting on the capped viral mRNA and pro-
tects from lethal vesicular stomatitis virus
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neuropathogenesis [56]. Gene expression distribution in
ridge plots of neutrophils, basal cells, dendritic cells, T
cells, and macrophages show that IFIT2 was expressed
higher in severe patients than the healthy or mild pa-
tients. IFIT2 expression is essential for an antiviral
response [57]. Thus, IFIT2 may have a function in the
host immune response [57].
Furthermore, CXCL2, CXCL,3, and CCL20 were found
upregulated and identified in early infection models of
SARS-CoV-2. Therefore, others proposed targeting these
Fig. 4 Potential SARS-CoV-2 infection mechanism influencing potential drug choices for repurposing. The SARS-CoV-2 virus enters the cells
through ACE2 receptors facilitated by TMPRSS2 and ADAM17. Drug molecules inhibiting the ACE2/TMPRSS2 axis dampen viral entry into the cell.
Angiotensin II also activates JAK/STAT pathways upregulating proinflammatory cytokines. IL-1, TNF-α cytokines are mediators of innate immunity
to stimulate an early innate response. These cytokines activate growth factor receptor pathways, such as PI3K/AKT and MAPK pathways leading to
increased proinflammatory cytokines production via the NF-kB transcription factor. Therefore, JAK/STAT, PI3K/AKT and MAPK inhibitors may be
beneficial in preventing inappropriate immune response. Inflammatory chemokines such as CXCL2, CXCL3, CCL20 attract other immune cell types
to fight the infection and repair tissue damage leading to local tissue inflammation and cytokine storm. Glucocorticoids may help immune
response associated with cytokine storm. G-protein coupled receptors, including bradykinin receptors and purinergic receptors, are also
associated with SARS-CoV-2 infection
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chemokine ligands as an effective therapeutic target dur-
ing viral infection [22]. In our CMAP query, it also was
found the knockdown of CXCL2 has a robust negative
connection (CS − 97.87), supporting this strategy. The
PPP1R15A was also critical for the survival of infected
cells and multiplication [52]. PPP1R15A expression was
reported higher in cells with very high levels of SARS-
CoV-2 RNA [53].
The signature developed in this study, from early tran-
scriptional changes due to SARS-CoV-2 infection, was
able to capture infection even in the postmortem lung
biopsy samples accurately. Thus, the gene signature not
only captures the putative gene expression but also pro-
vides a robust snapshot of the more persistent alter-
ations in gene expression due to SARS-CoV-2 infection
regardless of the duration of infection. Some of the
genes in the signatures showed differential expression in
various immune cells and may indicate the severity of
the infection. For example, TNFAIP3, PPP1R15A,
NFKBIA, and IFIT2 have bimodal gene expression in the
immune cells of severely infected patients compared to
healthy or mildly infected patients, while the chemokine
genes or chemokine inducible genes, IL1A, CXCL2,
CXCL3, CCL20, and PTX3 showed no variance. Overex-
pression of TNFAIP3, PPP1R15A, and NFKBIA genes in-
duces proinflammatory cytokines and interferons. On
the contrary, UPC2 showed decreased expression in den-
dritic cells, macrophages, and natural killer cells from se-
vere patients compared to healthy or mildly infected
individuals. Low UPC2 expression may indicate mito-
chondrial dysfunction, reactive oxygen species (ROS) ac-
cumulation, and more severe vascular disease [58, 59].
Cyclooxygenase (COX) inhibitors such as ibuprofen,
celecoxib negatively regulate the PI3K pathway. It has
been postulated that these inhibitors suppress NF-kb
and TNF-α induces JNK, MAPK, and ERK activation via
the AKT pathway, thus downregulating genes for inflam-
mation and proliferation [60]. Ibuprofen is a common
anti-inflammatory and antipyretic agent available over
the counter. For COVID-19 related fever and pain con-
trol, recommendations on using nonsteroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen in
COVID-19 have been inconsistent since the beginning
of the pandemic. French authorities initially recom-
mended against using ibuprofen in COVID-19 patients
due to a possible increased expression of the ACE2 re-
ceptor and likely risk of increased viral entry to cause
the infection. Later, this was disputed and several studies
were recommended continuing ibuprofen [61]. However,
in our CMAP query, ibuprofen had a strong negative
connection in lung, colon and hepatic cancer cell lines
(HCC515, HT29 and HEPG2, respectively) compared to
a strong positive connection in a renal cancer cell line
(HA1E) with the infection signature. Therefore,
depending on cell types, ibuprofen may show different
activities and the role of ibuprofen in COVID-19 treat-
ment needs to be explored further.
Both MEK and HDAC inhibitors are used as antican-
cer drugs and modulate the immune response, induce
cell cycle arrest, differentiation, and death. Additionally,
HDAC inhibitors have been shown to repress TMPR
SS2-ERG expression in prostate cancer [62, 63]. There-
fore, HDAC inhibitors’ role in suppressing TMPRSS2-
ERG may contribute to less efficient SARS-CoV-2 viral
entry into the cells. These drugs are costly and have ser-
ious side effects. On the other hand, antidepressants are
known for immunomodulatory effects, with several clas-
ses decreasing the production of proinflammatory cyto-
kines and increasing the production of anti-
inflammatory cytokines [64]. Maprotiline, a TCA, struc-
turally different from other TCAs, had a strong negative
connection in our analysis. Antidepressants such as
TCAs and selective serotonin reuptake inhibitors have
previously reported antiviral, immunomodulatory effects
and antioxidant properties [65]. Although data are lim-
ited on the innate and adaptive immune effects of TCAs,
they appear to have anti-inflammatory effects detected
via TNF-α and IL-6 [66].
There were several limitations to this study, including
the scarcity of publicly available SARS-CoV-2 transcrip-
tional, clinical, and drug response data preventing better
characterize of the virus’s role in drug response. A lim-
ited number of only 12 samples of 24-hour post-
infection were used to generate the signature. More di-
verse samples at various post-infection time points with
additional replicates may improve the robustness of the
signature. There was also limited signature data available
through CMAP database which uses cancer cell lines for
perturbation studies. Thus, the gene expression of hu-
man cells in vivo may be different than in these immor-
talized cell lines. Gene expression data from cell lines
treated with newer drugs, such as remdesivir or other
antivirals in clinical trials, are not available. This pre-
vented further validation of the signature in newer or ex-
cluded drugs. Gene expression-based analysis using a
single time point data provided a snapshot of the infec-
tion activity at that time point. The signature essentially
captured the minimal gene set to define the infection
status rather than early or late infection status. Although
our signature was able to accurately predict infection
status in patients with an unknown stage of SARS-CoV-
2 infection, future in vitro studies with serial time points
are required to better understand how the host response
evolves due to infection with time.
In this study, the present work demonstrated that
SARS-CoV-2 viral infection stimulates a unique re-
sponse in host cells captured by using the 25-gene signa-
ture. Select genes in the signature may also indicate the
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severity of the infection in the host. Additionally, several
potential drug targets were identified in the CMAP data-
base. In all, the SARS-CoV-2 signature may help ad-
vance our understanding of both infection mechanisms
and search for effective COVID-19 treatments.
Conclusion
The 25-gene SARS-CoV-2 infection signature accurately
predicted SARS-CoV-2 infection status in various lung
samples, such as BALF cells, PBMCs, and postmortem
lung biopsies in humans. Additionally, candidate SARS-
CoV-2 therapies were identified with this signature.
These signature genes may be utilized to determine the
disease severity of COVID-19 in the infected patients’
BALF single-cell expression profiles.
Methods
Datasets
This study aimed to generate and validate the SARS-
CoV-2 infection signature. The design and setting of the
study by using multiple publicly available datasets were
shown in Fig. S12. An RNA-Seq dataset from cell lines
and patient samples were downloaded from the NCBI
Gene Expression Omnibus (GEO) database (accession
no. GSE147507) [26]. Human-derived cell lines 24-hour
post-infection with SARS-CoV-2 and their associated
controls were included for the signature generation and
testing. Specifically, series 5, 6, 7, and 16 of cell lines
A549, A549-ACE2 (ACE2 overexpressed in A549 cell
line), Calu-3, infected with SARS-CoV-2 and mock-
treated were used as training sets, while series 2 and 15
were used as test sets [26]. Series 2 is A549 cell lines in-
fected with low SARS-CoV-2 infection (MOI 0.2) [26].
The A549 cells are known to have low expression of the
viral receptor ACE2. Therefore, A549 lung alveolar cells
are relatively non-permissive to SARS-CoV-2 replication
compared to Calu-3 cells, 0.1% versus 15% total reads,
respectively. However, ACE2 overexpressed in A549 cell
lines were used for signature generation, and series 2
(A549 cell lines without ACE2 overexpression) was used
for internal validation. Series 15 contained samples from
postmortem COVID19 patients and healthy lung biop-
sies (Table S3). This series was used to internally valid-
ate the signature in the patient samples.
Another independent validation dataset was down-
loaded from Genome Sequence Archive (GSA) in
National Genomics Data Center, Beijing Institute of
Genomics (BIG), Chinese Academy of Science (https://
bigd.big.ac.cn, accession no. CRA002390). Four BALF
samples from two patients with two replicates, PBMC
samples from three infected patients and three healthy
individuals were included in this dataset. Another data-
set of BALF samples from the healthy control RNA-Seq
dataset was obtained from the SRA database (SRAdb
sample ids SRR10571724, SRR10571730, SRR10571732;
Table S4) [67].
Finally, a scRNA-Seq dataset was used to comprehen-
sively characterize the signature genes in single cells
from BALF cells (GSE145926) [27]. scRNA-Seq data was
generated using the 10X genomics platform from BALF
cells of six severe/critical COVID-19 patients, three
moderate COVID-19 patients and three healthy
controls.
Bioinformatics analysis
Ingenuity pathway analysis and RNA-Seq data processing
Raw read counts from GSE147507 were normalized by
the DESeq2 median of ratios normalization method,
followed by the differentially expressed gene analysis
[68]. Genes with p-adj < 0.05 and log2FoldChange > 1
or < − 1 were considered as significantly differential
expressed genes (DEGs). Ingenuity Pathway Analysis
(IPA) was used to analyze the biological enrichment
pathway of SARS-CoV-2 with DEGs [69]. FastQC was
utilized to perform quality control for the raw fastq files
of CRA002390, SRR10571724, SRR10571730, and
SRR10571732 [70]. Sequencing reads were processed for
library adapter removal and initial filtering by using
Trimmomatic [71]. The STAR software package was
used to align reads to a human reference genome
(GRCH38) [72]. PCR replicates mapped in the human
genome were removed with picard MarkDuplicates pro-
gram (v2.22.7) [73]. Then, featureCounts was used to
quantify the reads [74].
Batch adjustment
To minimize confounding batch effects between the dif-
ferent series of data, further data processing was per-
formed. First, variances between the different cell line
data were visualized using principal component analysis
(PCA) [19, 75]. Significant batch effects were observed
between all training and test RNA-Seq datasets. Using
the ComBat function from the R package sva (v3.34.0),
confounding batch effects were adjusted [76]. Within the
GSE147507 dataset, the batch adjustment was performed
considering each series separately since each series had
different cell types with different MOIs. Following batch
adjustment, a second PCA was performed to confirm
the resolution of the batch effect. Series 5, 6, 7, and 16
were separated into two major groups — mock-treated
and SARS-CoV-2 infected samples to generate
signatures.
Signature generation and validation
To identify the minimum set of genes representing the
status of the SARS-CoV-2 infection, cell line data were
acquired from the NCBI GEO database (GSE147507).
First, data were normalized by using the DESeq2 median
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of ratio method, followed by batch adjustment using the
ComBat function from the sva R package (Version
3.34.0). Adaptive Signature Selection and InteGratioN
(ASSIGN; version 1.9.1) was utilized to generate the
gene signature representative of SARS-CoV-2 infection
[25]. ASSIGN is a semi-supervised pathway profiling
toolkit that uses the Bayesian variable selection approach
to different genes expressing a biological condition, such
as SARS-CoV-2 infection for this study [25]. These
genes were selected based on their signal strengths and
weights, where the higher the value generated, the more
significant contribution of the genes to the SARS-CoV-2
infection-related transcriptional activity [25].
With ASSIGN using the assign.wrapper function with
default settings, gene signatures were generated by pro-
ducing gene list lengths consisting of 25 genes ranging
to 500 genes. The gene lists were produced in 25 gene
increments, e.g., 25, 50, 75, 100, 125, and so on, up to
500 genes. SARS-CoV-2 infection activity was analyzed
for each training sample using LOOCV. Predicted infec-
tion activity values generated ranged between zero to
one, where “0” indicates no infection, and “1” indicates
maximum infection activity. Series 5, 6, 7, and 16 were
specified as the training datasets, while series 15 and 2
were test datasets. Series 2, A549 cell lines, consisted of
control and very low SARS-CoV-2 infected samples, and
series 15 dataset contained postmortem lung biopsy
samples from patients with and without SARS-CoV-2 in-
fection. While running each prediction in test and valid-
ation datasets, ASSIGN’s adaptive background feature
was used to further correct the background transcrip-
tional variation due to the cell line-specific and back-
ground gene expression variances. Finally, an
independent external validation was performed in RNA-
Seq datasets (CRA002390, SRR10571724, SRR10571730,
and SRR10571732) from COVID-19 patients and healthy
controls.
Characterization of signature genes in single cells
R package Seurat was used for data (GSE145926)
normalization with NormalizeData function. Feature
counts of each cell were divided by the total counts for
that cell multiplied by a scaler factor (1e6), then natural-
log transformed [77]. The normalized data were then in-
tegrated for batch effect adjustment and Uniform mani-
fold approximation and projection (UMAP) clustering
[77]. After a quality control check, FindALLMarkers was
used to find cell markers for all clusters. Clusters were
annotated based on canonical cell markers (Table S1).
Different cell types were identified in severe/critical,
moderate patients, and healthy control samples. Signa-
ture genes from the RNA-Seq data were evaluated in the
scRNA-Seq dataset by using the DoHeatmap function
with scaled expression values. RidgePlot was used to
generate the distribution of signature genes’ expressions
in various types of cells.
Analysis of SARS-CoV-2 transcriptional activity for
perturbagen detection
CSs were assessed with the signature gene list using a
CMAP query to identify the most similar and dissimilar
perturbagen signatures to our SARS-CoV-2 infection
signature in the CMAP database with more than a mil-
lion perturbation experiments [78]. The CMAP query
finds similarities and dissimilarities across the curated
expression profiles of various perturbations, including
compounds, overexpressions, and knockdowns. CS is a
quantitative score between a query gene-list and a per-
turbagen that ranges from − 100 (opposing signature) to
100 (same signature). CS of − 90 or lower for dissimilar-
ity and 90 or higher for similarity were considered as
strong connections.
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